Overactive bladder could be a medical syndrome, outlined by urinary incontinence typically characterised by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are thought-about because the initial line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are a number of the generic drugs used for the treatment of overactive bladder. These medicine acts by antagonizing cholinergic receptors that has the relief from the frequent urination.
The Overactive Bladder Treatment market is expected to grow from USD 4.08 billion in 2019 to USD 5.04 billion by 2025 at a CAGR of 3.07% from 2020 to 2026.
Overactive bladder could be a medical syndrome, outlined by urinary incontinence typically characterised by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are thought-about because the initial line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are a number of the generic drugs used for the treatment of overactive bladder. These medicine acts by antagonizing cholinergic receptors that has the relief from the frequent urination.
The global Overactive Bladder Treatment market is segregated on the basis of Therapy Type as Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics*, Mirabegron, and BOTOX. Based on Disease the global Overactive Bladder Treatment market is segmented in Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.
The global Overactive Bladder Treatment market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Overactive Bladder Treatment market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Astellas Pharma Inc. , Pfizer, Inc. , Teva Pharmaceutical Industries Limited , Allergan, PLC. , Mylan N.V. , Endo International PLC , Hisamitsu Pharmaceutical Co., Inc. , Sanofi , Aurobindo Pharma Limited , Johnson & Johnson , and others are among the major players in the global Overactive Bladder Treatment market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.
The global Overactive Bladder Treatment market has been segmented as below:
Overactive Bladder Treatment Market, By Therapy Type
Overactive Bladder Treatment Market, By Disease
Overactive Bladder Treatment Market, By Region
Overactive Bladder Treatment Market, By Company
The report covers the below scope:
The years considered for the study are as follows:
Report Scope:
The global Overactive Bladder Treatment market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Overactive Bladder Treatment market share. Major industry players with significant revenue share include Astellas Pharma Inc. , Pfizer, Inc. , Teva Pharmaceutical Industries Limited , Allergan, PLC. , Mylan N.V. , Endo International PLC , Hisamitsu Pharmaceutical Co., Inc. , Sanofi , Aurobindo Pharma Limited , Johnson & Johnson , and others.
Why to Buy this Report:
Target Audience:
The report targeted towards the existing players in the industry is as follows:
Free and Paid Customization based on the requirement
Report Content
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter''s Five Force Analysis
5.1 Introduction
5.2 Anticholinergics
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Solifenacin
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Oxybutynin
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Darifenacin
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Fesoterodine
5.6.1 Market Overview
5.6.2 Market Size and Forecast
5.7 Tolterodine
5.7.1 Market Overview
5.7.2 Market Size and Forecast
5.8 Trospium
5.8.1 Market Overview
5.8.2 Market Size and Forecast
5.9 Other Anticholinergics*
5.9.1 Market Overview
5.9.2 Market Size and Forecast
5.10 Mirabegron
5.10.1 Market Overview
5.10.2 Market Size and Forecast
5.11 BOTOX
5.11.1 Market Overview
5.11.2 Market Size and Forecast
6.1 Introduction
6.2 Idiopathic Bladder Overactivity
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Neurogenic Bladder Overactivity
6.3.1 Market Overview
6.3.2 Market Size and Forecast
7.1 Introduction
7.2 North America
7.2.1 North America Overactive Bladder Treatment, By Therapy Type
7.2.2 North America Overactive Bladder Treatment, By Disease
7.3 Europe
7.3.1 Europe Overactive Bladder Treatment, By Therapy Type
7.3.2 Europe Overactive Bladder Treatment, By Disease
7.4 Asia-Pacific
7.4.1 Asia-Pacific Overactive Bladder Treatment, By Therapy Type
7.4.2 Asia-Pacific Overactive Bladder Treatment, By Disease
7.5 Rest of the World
7.5.1 Rest of the World Overactive Bladder Treatment, By Therapy Type
7.5.2 Rest of the World Overactive Bladder Treatment, By Disease
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
The global Overactive Bladder Treatment market has been segmented as below:
Overactive Bladder Treatment Market, By Therapy Type
Overactive Bladder Treatment Market, By Disease
Overactive Bladder Treatment Market, By Region
Overactive Bladder Treatment Market, By Company